EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study

Luca Pellegrini, Naomi A Fineberg, Sorcha O'Connor, Ana Maria Frota Lisboa Pereira De Souza, Kate Godfrey, Sara Reed, Joseph Peill, Mairead Healy, Cyrus Rohani-Shukla, Hakjun Lee, Robin Carhart-Harris, Trevor W Robbins und 2 weitere

Comprehensive Psychiatry · 2025-10 · 142 · 152619

DOI: 10.1016/j.comppsych.2025.152619 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Comprehensive Psychiatry, 2025-10. Verfasst von Luca Pellegrini und 13 weiteren Autor:innen. Beteiligte Einrichtung: School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom; Centre for Neuropsychopharmacology and Psychedelic Resear…. Hauptthemen laut MEDLINE: Obsessive-Compulsive Disorder, Psilocybin, Hallucinogens. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Imperial College London.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Obsessive-compulsive disorder (OCD) is a common and disabling condition. A large proportion of patients fail to respond to first-line treatment with serotonin reuptake inhibitors either selective serotonin reuptake inhibitors (SSRIs) or clomipramine. Preliminary evidence suggests psilocybin, a serotonin receptor agonist, might be efficacious. We conducted a pharmacological challenge study to investigate the efficacy and mechanisms of effect of psilocybin in OCD. This analysis reports the clinical outcomes only. METHODS: Participants with a diagnosis of OCD of at least moderate severity, received two single doses of oral psilocybin, 1 mg followed by 10 mg, administered in fixed order separated by 4 weeks. On the day of dosing, they were treated in a day-care facility in the presence of clinicians experienced in the use of psychedelics for treating mental disorders. Psychological support was provided before, during and after dosing. Participants and raters were blinded to the order of treatment. They were assessed on the day before each dose (baseline 1, 2), on the day of dosing and at intervals over a 4-week period afterward using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) (primary clinical outcome) and secondary clinical outcomes including the Montgomery-Åsberg Depression Rating Scale (MADRS). Adverse effects were also recorded. RESULTS: Nineteen adult participants (aged 20-60) entered the study and 18 completed all assessments. Clinical outcomes following 1 mg and 10 mg psilocybin were compared using a linear mixed-effects model and ANOVA. A significant between-dosage effect favouring 10 mg psilocybin was found one-week after dosing on the Y-BOCS (Cohen's d = 0.82, p = 0.002). In particular, the effect one-week after dosing was statistically significant on the compulsion subscale of the Y-BOCS (Cohen's d: 0.74, p = 0.003), compared to obsession (Cohen's d: 0.50, p = 0.06). The effect diminished over the subsequent 3 weeks. No effect of psilocybin was detected on the MADRS. Psilocybin was well tolerated, with few adverse events reported at both dosages and no serious adverse events. CONCLUSIONS: In this study, which was limited by a small sample size and the absence of randomisation, a 10 mg dose of oral psilocybin was found to be well-tolerated and potentially efficacious in patients with OCD. Psilocybin produced a rapid-onset, moderate to large effect on compulsive symptoms, which lasted up to one week after dosing. Future randomised placebo-controlled clinical trials investigating a longer course of multiple weekly doses of 10 mg psilocybin are indicated in OCD and in other obsessive-compulsive and related disorders characterised by compulsions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Obsessive-Compulsive DisorderPsilocybinHallucinogensHumansAdultMaleFemaleMiddle AgedTreatment OutcomePsychiatric Status Rating ScalesYoung Adult

Stichwörter der Autor:innen

CompulsionsOCDOssessive-compulsive disorderPsilocybinPsychedelics

Substanzen

PsilocybinHallucinogens

Autor:innen und Institutionen

  • School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom; Centre for Neuropsychopharmacology and Psychedelic Research, Hammersmith Hospital Campus, Imperial College, London, United King…
  • School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom; Hertfordshire Partnership University NHS Foundation Trust, Welwyn Garden City, United Kingdom; University of Cambridge School o…
  • Centre for Neuropsychopharmacology and Psychedelic Research, Hammersmith Hospital Campus, Imperial College, London, United Kingdom.
  • School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom.
  • Behavioural and Clinical Neuroscience Institute, Department of Psychology, University of Cambridge, Cambridge, United Kingdom.
  • Centre for Neuropsychopharmacology and Psychedelic Research, Hammersmith Hospital Campus, Imperial College, London, United Kingdom; Psychedelics Division, Neurology, Psychiatry and Behavioural Sciences Weill Institute f…

Förderung

  • Imperial College London

Zitieren

APA

Pellegrini, L., Fineberg, N. A., O'Connor, S., De Souza, A. M. F. L. P., Godfrey, K., Reed, S., Peill, J., Healy, M., Rohani-Shukla, C., Lee, H., Carhart-Harris, R., Robbins, T. W., Nutt, D., & Erritzoe, D. (2025). Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study. Comprehensive Psychiatry, 142, 152619. https://doi.org/10.1016/j.comppsych.2025.152619

Vancouver

Pellegrini L, Fineberg NA, O'Connor S, De Souza AMFLP, Godfrey K, Reed S, et al. Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study. Comprehensive Psychiatry. 2025;142:152619. doi:10.1016/j.comppsych.2025.152619

BibTeX
@article{Pellegrini2025,
  author = {Pellegrini, Luca and Fineberg, Naomi A and O'Connor, Sorcha and De Souza, Ana Maria Frota Lisboa Pereira and Godfrey, Kate and Reed, Sara and Peill, Joseph and Healy, Mairead and Rohani-Shukla, Cyrus and Lee, Hakjun and Carhart-Harris, Robin and Robbins, Trevor W and Nutt, David and Erritzoe, David},
  title = {Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study},
  journal = {Comprehensive Psychiatry},
  year = {2025},
  volume = {142},
  pages = {152619},
  doi = {10.1016/j.comppsych.2025.152619}
}
Kostenlos starten →